Given the critical role of p53 mutations in cancer, there is significant interest in developing targeted therapies to restore p53 function or counteract its effects. Approaches include small molecules that can reactivate mutant p53, such as PRIMA-1 and APR-246, which have shown promise in preclinical studies and early-phase clinical trials. Additionally, strategies that target pathways activated by mutant p53, including inhibitors of MDM2 (a negative regulator of p53) and compounds that modulate the p53-dependent apoptotic pathway, are under investigation.
